6-hydroxynorketamine has been researched along with ketamine in 35 studies
*Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. [MeSH]
*Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. [MeSH]
| Studies (6-hydroxynorketamine) | Trials (6-hydroxynorketamine) | Recent Studies (post-2010) (6-hydroxynorketamine) | Studies (ketamine) | Trials (ketamine) | Recent Studies (post-2010) (ketamine) |
|---|---|---|---|---|---|
| 38 | 2 | 36 | 15,029 | 2,321 | 6,678 |
| Protein | Taxonomy | 6-hydroxynorketamine (IC50) | ketamine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 3.7762 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 3.5563 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 4.1059 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 21 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baillie, TA; Leung, LY | 1 |
| Brutsche, NE; Ibrahim, L; Luckenbaugh, DA; Mager, DE; Moaddel, R; Venkata, SL; Wainer, IW; Zarate, CA; Zhao, X | 1 |
| Dahan, A; van Velzen, M | 1 |
| Bernier, M; Green, CE; Khadeer, M; Moaddel, R; O'Loughlin, K; Paul, RK; Sanghvi, M; Singh, NS; Torjman, MC; Wainer, IW | 1 |
| Malinow, R | 1 |
| Albuquerque, EX; Alkondon, M; Dossou, KS; Elmer, GI; Fang, Y; Fischell, J; Georgiou, P; Gould, TD; Huang, XP; Mayo, CL; Moaddel, R; Morris, PJ; Pribut, HJ; Singh, NS; Thomas, CJ; Thompson, SM; Wainer, IW; Yuan, P; Zanos, P; Zarate, CA | 1 |
| Abe, M; Chaki, S; Hashimoto, K; Nozawa, D; Qu, Y; Yang, C | 1 |
| Jokinen, V; Kalso, EA; Lilius, TO; Niemi, M; Rauhala, PV; Viisanen, H | 1 |
| Chaki, S; Hashimoto, K; Koike, H; Mizuno-Yasuhira, A; Qu, Y; Toki, H; Yamaguchi, JI; Yang, C | 1 |
| Chen, GD; Chou, D; Ho, YC; Hsieh, MC; Lai, CY; Lee, AS; Lin, TB; Peng, HY; Wang, HH; Wen, YC; Yang, PS | 1 |
| Chaki, S; Yamaguchi, JI | 1 |
| Chang, L; Chen, J; Fujita, Y; Hashimoto, K; Ma, M; Pu, Y; Xiong, Z; Zhang, K | 1 |
| Chou, D; Huang, Y; Ko, CY; Ye, L; Zheng, C; Zheng, Y | 1 |
| Albuquerque, EX; Aracava, Y; Fischell, J; Gould, TD; Pereira, EFR; Riggs, LM; Thompson, SM; Zanos, P | 1 |
| Burke, AK; Choo, TH; Cooper, TB; Galfalvy, HC; Grunebaum, MF; Mann, JJ; Parris, MS; Suckow, RF | 1 |
| DiLeone, RJ; Duman, RS; Hare, BD; Pothula, S | 1 |
| Ali, T; Hao, Q; He, K; Li, S; Li, Y; Rahman, SU; Yang, X; Ye, T; Zhou, Q | 1 |
| Chou, D | 1 |
| Herzog, DP; Lutz, B; Mellema, RM; Müller, MB; Remmers, F; Treccani, G | 1 |
| Brachman, RA; Chen, BK; Cooper, TB; David, DJ; Deng, SX; Denny, CA; Gardier, AM; LaGamma, CT; Landry, DW; Luna, VM; Mendez-David, I; Shah, A; Suckow, RF; Xu, X | 1 |
| Aleksandrova, LR; Phillips, AG; Wang, YT | 1 |
| Elmer, GI; Gould, TD; Mayo, CL; Tapocik, JD; Zanos, P | 1 |
| Aguilar-Valles, A; Bermudez, S; De Gregorio, D; Eslamizade, MJ; Gobbi, G; Khlaifia, A; Lacaille, JC; Lopez-Canul, M; Matta-Camacho, E; Rurak, GM; Salmaso, N; Simard, S; Skaleka, A; Sonenberg, N; Torres-Berrio, A | 1 |
| Bokel, A; Hutter, MC; Urlacher, VB | 1 |
| Brannigan, G; Bu, W; Eckenhoff, RG; Joseph, TT; Lin, W; Liu, R; Yeliseev, A; Zoubak, L | 1 |
| Siegmund, W; Weiss, M | 1 |
| An, X; Gould, TD; Pereira, EFR; Riggs, LM | 1 |
| Gould, TD; Hagen, NR; Highland, JN; Konrath, KM; Moaddel, R; Morris, PJ; Powels, CF; Riggs, LM; Thomas, CJ; Wang, AQ; Zanos, P | 1 |
| Chen, S; Chou, D; Du, Y; Li, L; Li, Z; Liu, B; Luo, T; Qin, W; Xiao, X; Xu, Y; Ye, L; Yuan, Y; Zheng, C | 1 |
| Ju, L; Liu, P; Yang, J; Zhu, T | 1 |
| Browne, CA; Lucki, I; Wulf, HA; Zarate, CA | 1 |
| Gould, TD; Riggs, LM; Thompson, SM | 1 |
| Bonaventura, J; Carlton, ML; Gomez, JL; Gould, TD; Kang, HJ; Lam, S; Michaelides, M; Moaddel, R; Morris, PJ; Sanchez-Soto, M; Sibley, DR; Thomas, CJ; Zanos, P; Zarate, CA | 1 |
| Browne, CA; Lucki, I; Yost, JG | 1 |
| Chen, Y; Lai, J; Wei, S; Yan, P; Zhou, Q; Zhu, Y | 1 |
2 trial(s) available for 6-hydroxynorketamine and ketamine
| Article | Year |
|---|---|
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
Topics: Adult; Algorithms; Antidepressive Agents; Biotransformation; Bipolar Disorder; Cross-Over Studies; Double-Blind Method; Drug Resistance; Female; Humans; Hydroxylation; Infusions, Parenteral; Ketamine; Male; Middle Aged; Models, Biological; Young Adult | 2012 |
Ketamine metabolite pilot study in a suicidal depression trial.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Infusions, Parenteral; Ketamine; Midazolam; Outcome Assessment, Health Care; Pilot Projects; Severity of Illness Index; Suicidal Ideation | 2019 |
33 other study(ies) available for 6-hydroxynorketamine and ketamine
| Article | Year |
|---|---|
Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine.
Topics: Anesthesia; Animals; Brain; Ketamine; Male; Rats; Rats, Inbred Strains | 1986 |
Ketamine metabolomics in the treatment of major depression.
Topics: Animals; Excitatory Amino Acid Antagonists; Ketamine; Male; TOR Serine-Threonine Kinases | 2014 |
(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.
Topics: Aconitine; Animals; Blotting, Western; Brain; Excitatory Amino Acid Antagonists; Ketamine; Male; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; PC12 Cells; Phosphorylation; Prefrontal Cortex; Rats; Rats, Wistar; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Depression: Ketamine steps out of the darkness.
Topics: Animals; Antidepressive Agents; Female; Ketamine; Male | 2016 |
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Topics: Animals; Antidepressive Agents; Female; Ketamine; Male; Mice; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Time Factors | 2016 |
(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dominance-Subordination; Inflammation; Ketamine; Lipopolysaccharides; Male; Mice, Inbred C57BL; Stereoisomerism; Stress, Psychological; Time Factors | 2017 |
Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Behavior, Animal; Brain; Disease Models, Animal; Drug Interactions; Drug Tolerance; Ketamine; Male; Morphine; Motor Activity; Nociception; Nociceptive Pain; Pain Threshold; Rats, Sprague-Dawley | 2018 |
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
Topics: Animals; Antidepressive Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Depressive Disorder; Inflammation; Ketamine; Lipopolysaccharides; Male; Mice, Inbred C57BL; Mice, Inbred ICR | 2018 |
(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
Topics: Animals; Antidepressive Agents; Cell Membrane; Cytosol; Depressive Disorder; Disease Models, Animal; Excitatory Postsynaptic Potentials; Female; Glutamic Acid; Helplessness, Learned; Ketamine; Male; Miniature Postsynaptic Potentials; Neurons; Periaqueductal Gray; Rats, Sprague-Dawley; Receptors, AMPA; Stress, Psychological; Synapses; Tissue Culture Techniques | 2018 |
Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug.
Topics: Animals; Antidepressive Agents; Humans; Ketamine; Stereoisomerism | 2018 |
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Biomarkers; Bone Density; Depression; Depressive Disorder; Disease Models, Animal; Inflammation; Ketamine; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Osteopontin; Osteoprotegerin; RANK Ligand; Stress, Psychological | 2019 |
Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Aggression; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; Female; Ketamine; Male; Microinjections; Miniature Postsynaptic Potentials; Periaqueductal Gray; Rats; Synaptic Transmission | 2019 |
(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
Topics: Animals; Excitatory Postsynaptic Potentials; Female; Glutamic Acid; Hippocampus; Ketamine; Male; Organ Culture Techniques; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Synapses; Synaptic Transmission | 2020 |
Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.
Topics: Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Ketamine; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Photometry; Prefrontal Cortex; Stereoisomerism | 2020 |
Proteomic Study Reveals the Involvement of Energy Metabolism in the Fast Antidepressant Effect of (2R, 6R)-Hydroxy Norketamine.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Computational Biology; Energy Metabolism; Gene Ontology; Glycolysis; Ketamine; Male; Mice; Mice, Inbred BALB C; Proteomics; Tandem Mass Spectrometry | 2020 |
Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
Topics: Aggression; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Female; Ketamine; Male; Periaqueductal Gray; Rats; Rats, Sprague-Dawley | 2020 |
Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hydroxynorketamine Administration.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Nucleus; Disease Models, Animal; Female; Green Fluorescent Proteins; Hippocampus; Ketamine; Male; Memory, Episodic; Mice, Transgenic; Neurons; Recombination, Genetic; Sex Characteristics; Social Behavior | 2020 |
Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
Topics: Animals; Electrophysiological Phenomena; Female; Hippocampus; Ketamine; Male; Mice; Receptors, N-Methyl-D-Aspartate | 2020 |
Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression.
Topics: Animals; Depression; Disease Models, Animal; Hippocampus; Immobilization; Ketamine; Long-Term Potentiation; Male; Motor Activity; Open Field Test; Rats, Inbred WKY; Spatial Memory; Stress, Psychological; Swimming; Synaptic Transmission | 2020 |
Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Female; Ketamine; Male; Mice; Mice, Inbred C57BL; Predatory Behavior; Stress, Psychological | 2020 |
Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antidepressive Agents; Cell Cycle Proteins; Depressive Disorder, Major; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factors; Excitatory Postsynaptic Potentials; Hippocampus; Inhibitory Postsynaptic Potentials; Interneurons; Ketamine; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mutation; Neural Inhibition; Neurons; Protein Biosynthesis; Pyramidal Cells; Synaptic Transmission | 2021 |
Molecular evolution of a cytochrome P450 for the synthesis of potential antidepressant (2R,6R)-hydroxynorketamine.
Topics: Antidepressive Agents; Bacterial Proteins; Catalytic Domain; Cytochrome P-450 Enzyme System; Evolution, Molecular; Hydroxylation; Ketamine; Molecular Docking Simulation; Mutation; Oxidation-Reduction; Protein Binding; Streptomyces coelicolor; Thermobifida | 2021 |
Ketamine Metabolite (2
Topics: Antidepressive Agents; Depression; Ketamine; Receptors, Opioid, kappa | 2021 |
Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines.
Topics: Analgesics; Antidepressive Agents; Humans; Ketamine; Stereoisomerism | 2022 |
(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency.
Topics: Animals; Antidepressive Agents; Female; Ketamine; Male; Mice | 2021 |
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Female; Ketamine; Male; Mice | 2022 |
Prelimbic cortex miR-34a contributes to (2R,6R)-hydroxynorketamine-mediated antidepressant-relevant actions.
Topics: Animals; Antidepressive Agents; Female; Ketamine; Male; Mice; Mice, Inbred C57BL; MicroRNAs | 2022 |
BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depression; Disease Models, Animal; Female; Ketamine; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Receptor, trkB; Up-Regulation | 2022 |
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Humans; Ketamine; Mice; Naltrexone; Receptors, Opioid, kappa | 2022 |
(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity.
Topics: Animals; Antidepressive Agents; Glutamic Acid; Hippocampus; Ketamine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.
Topics: Antidepressive Agents; Humans; Ketamine; Tissue Distribution | 2022 |
(2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory pain.
Topics: Animals; Antidepressive Agents; Female; Inflammation; Ketamine; Male; Mice; Mice, Inbred C57BL; Neuralgia | 2022 |
Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice.
Topics: Analgesics, Opioid; Animals; Anxiety; Anxiety Disorders; Ketamine; Male; Mice; Morphine; Neurons; Nucleus Accumbens; Parvalbumins; Potassium | 2023 |